Multiple Ascending Dose of BMS-911543

A Phase 1/2 Multiple Ascending Dose Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of BMS-911543 in Subjects With Myelofibrosis

The purpose of this first in human study is to determine if BMS-911543 is safe and tolerable in subjects with symptomatic intermediate-1, intermediate-2 or high risk myelofibrosis to permit clinical testing at the Maximum Tolerated Dose or at a Clinically Active Dose, and to determine if BMS-911543 will demonstrate efficacy in symptomatic myelofibrosis.

Study Overview

• Status: Terminated
• Conditions: Cancer
• Intervention / Treatment: Drug: BMS-911543

• Study Type: Interventional
• Enrollment (Actual): 98
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• Australia
  • Victoria
    • East Melbourne, Victoria, Australia, 3002
      • Local Institution
    • Melbourne, Victoria, Australia, 3050
      • Local Institution
• United States
  • Minnesota
    • Rochester, Minnesota, United States, 55905
      • Mayo Clinic
  • New York
    • New York, New York, United States, 10029
      • The Mount Sinai School of Medicine
  • Texas
    • Houston, Texas, United States, 77030
      • The University of Texas MD Anderson Cancer Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.

Inclusion Criteria:

• Men and Women at least 18 years old
• A diagnosis of symptomatic, primary or secondary Myelofibrosis (MF) [World Health Organization (WHO) 2008 criteria] with intermediate-1, intermediate-2 or high risk disease as assessed using the Dynamic International Prognostic Scoring System international prognostic scoring system
• Last therapeutic or diagnostic treatment at least 28 days prior
• Any toxicity from prior therapies must have resolved to Grade ≤1
• Adequate Liver and Kidney Function
• Serum amylase and lipase within normal institutional range
• Platelet count ≥50,000 cell mm³
• Absolute neutrophil count (ANC) ≥1,000 cells/mm3
• Hemoglobin ≥8.0 g/dL

Exclusion Criteria:

• Primary central nervous system tumors
• Subjects with currently active malignancy (other than MF) or with a prior history of malignancy with the exception of: (i) adequately treated basal cell carcinoma of the skin, (ii) curatively treated in situ carcinoma of the cervix, (iii) other malignancy that has undergone potentially curative therapy with no evidence of disease recurrence ≥3 years
• Any condition requiring chronic use of moderate/high dose steroids except inhalation or oral steroids for mild pulmonary disease
• Splenic irradiation ≤3 months prior to treatment with study drug
• Positive blood screen for hepatitis C antibody, hepatitis B surface antigen or Human Immunodeficiency Virus-1 (HIV-1), or HIV-2 antibodies
• Abnormalities in serum electrolytes
• Significant cardiovascular disease
• Current or recent gastrointestinal disease
• Previous history of pancreatitis and/or significant risk factors for pancreatitis as judged by the treating physician
• Evidence of uncontrolled active infection or active graft vs. host disease
• Inability to tolerate oral medication

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

12

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Phase 1 (Cohort 1): BMS-911543 (5 mg); BMS-911543 5 mg capsule by mouth twice daily for 12 months or greater depending on response	Drug: BMS-911543; Other Names: JAK2 Inhibitor
Experimental: Phase 1 (Cohort 2): BMS-911543 (10 mg); BMS-911543 10 mg capsule by mouth twice daily for 12 months or greater depending on response	Drug: BMS-911543; Other Names: JAK2 Inhibitor
Experimental: Phase 1 (Cohort 3): BMS-911543 (20 mg); BMS-911543 20 mg capsule by mouth twice daily for 12 months or greater depending on response	Drug: BMS-911543; Other Names: JAK2 Inhibitor
Experimental: Phase 1 (Cohort 4): BMS-911543 (40 mg); BMS-911543 40 mg capsule by mouth twice daily for 12 months or greater depending on response	Drug: BMS-911543; Other Names: JAK2 Inhibitor
Experimental: Phase 1 (Cohort 5): BMS-911543 (80 mg); BMS-911543 80 mg capsule by mouth twice daily for 12 months or greater depending on response	Drug: BMS-911543; Other Names: JAK2 Inhibitor
Experimental: Phase 1 (Cohort 6): BMS-911543 (120 mg); BMS-911543 120 mg capsule by mouth twice daily for 12 months or greater depending on response	Drug: BMS-911543; Other Names: JAK2 Inhibitor
Experimental: Phase 1 (Cohort 7): BMS-911543 (160 mg); BMS-911543 160 mg capsule by mouth twice daily for 12 months or greater depending on response	Drug: BMS-911543; Other Names: JAK2 Inhibitor
Experimental: Phase 1 (Cohort 8): BMS-911543 (200 mg); BMS-911543 200 mg capsule by mouth twice daily for 12 months or greater depending on response	Drug: BMS-911543; Other Names: JAK2 Inhibitor
Experimental: Phase 1 (Cohort 9): BMS-911543 (240 mg); BMS-911543 240 mg capsule by mouth twice daily for 12 months or greater depending on response	Drug: BMS-911543; Other Names: JAK2 Inhibitor
Experimental: Phase 1 (Cohort 10): BMS-911543 (320 mg); BMS-911543 320 mg capsule by mouth twice daily for 12 months or greater depending on response	Drug: BMS-911543; Other Names: JAK2 Inhibitor
Experimental: Phase 2 (Cohort 11): BMS-911543 (120 mg); BMS-911543 120 mg capsule by mouth twice daily for 12 months or greater depending on response	Drug: BMS-911543; Other Names: JAK2 Inhibitor
Experimental: Phase 2 (Cohort 12): BMS-911543 (200 mg); BMS-911543 200 mg capsule by mouth twice daily for 12 months or greater depending on response	Drug: BMS-911543; Other Names: JAK2 Inhibitor

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants With Adverse Events	Safety assessments were based on a medical review of adverse event reports and the results of vital sign measurements, ECGs, physical examinations, and clinical laboratory tests and were evaluated for all treated participants using National Cancer Institute Common Terminology Criteria for Adverse Events v4.0 (NCI CTCAE v.4.0).	From the date of participant's written consent until 30 days post discontinuation of dosing or participation in the study if the last scheduled visit occured at a later time, assessed up to 4.5 years
Number of Participants With Best Overall Response	Participants were clinically assessed for IWG-(International Working Group consensus criteria for treatment response in myelofibrosis with myeloid metaplasia) defined response at each returning on-treatment visit and the first post-treatment visit. IWG-MRT criteria for best overall response are ordered high to low: CR>PR>CI>SD>PD>R where CR = Complete Remission, PR= Partial Remission, CI = Clinical Improvement, SD = Stable Disease, PD = Progressive Disease and R = Relapse. Best overall response is the best response of the subject during the treatment period or at the first post-treatment visit.	Day 1, at each returning on-treatment visit and the first post-treatment visit

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Changes in (Janus Kinase) JAK/Signal Transducers and Activators of Transcription (STATs) Pathway Activities, Circulating CD34+ Cells and Plasma Cytokine Levels	JAK/STAT pathway activity will be evaluated by: 1) pSTATs levels using immunoassay; 2) expression levels of several JAK/STATs pathway genes. Whole blood will be collected at specific time-points. Due to portfolio/business decisions by the sponsor, the compound is no longer being developed and the study was terminated. Analysis was not completed because the study was terminated. This decision was not based on any safety concerns associated with BMS-911543.	Up to 6 months
Maximum Observed Plasma Concentration (Cmax) of BMS-911543 and it's Metabolite BMS-926796 (Met4)	Pharmacokinetic parameters of BMS-911543 and BMS-926796 (Met4) metabolite, will be derived from plasma concentration versus time. The pharmacokinetic parameters to be assessed include: Cmax Maximum observed plasma concentration	Day -1, Day 1, Day 8, Day 15, Day 21 and Day 28 or off-study
Trough Observed (Pre-dose) Plasma Concentration (Cmin) of BMS-911543 and it's Metabolite Met4	Pharmacokinetic parameters of BMS-911543 and BMS-926796 (Met4) metabolite, will be derived from plasma concentration versus time. The pharmacokinetic parameters to be assessed include: Cmin (Trough observed (pre-dose) plasma concentration)	Day -1, Day 1, Day 8, Day 15, Day 21 and Day 28 or off-study
Time of Maximum Observed Plasma Concentration (Tmax) of BMS-911543 and it's Metabolite Met4	Pharmacokinetic parameters of BMS-911543 and BMS-926796 (Met4) metabolite, will be derived from plasma concentration versus time. The pharmacokinetic parameters to be assessed include: Tmax = Time of maximum observed plasma concentration (Tmax) of BMS-911543 and it's metabolite Met4	Day -1, Day 1, Day 8, Day 15, Day 21 and Day 28 or off-study
Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinite Time (for Single Dose Period Only) (AUC(INF)) of BMS-911543 and it's Metabolite Met4	Pharmacokinetic parameters of BMS-911543 and BMS-926796 (Met4) metabolite, will be derived from plasma concentration versus time. The pharmacokinetic parameters to be assessed include: AUC(INF) = Area under the plasma concentration-time curve from time zero extrapolated to infinite time (for single dose period only) (AUC(INF)) of BMS-911543 and it's metabolite Met4	Day -1, Day 1, Day 8, Day 15, Day 21 and Day 28 or off-study
Area Under the Plasma Concentration-time Curve From Time Zero to the Time of Last Quantifiable Plasma Concentration (for Single Dose Period Only) (AUC(0-T)) of BMS-911543 and it's Metabolite Met4	Pharmacokinetic parameters of BMS-911543 and BMS-926796 (Met4) metabolite, will be derived from plasma concentration versus time. The pharmacokinetic parameters to be assessed include: AUC (0-T) = Area under the plasma concentration-time curve from time zero to the time of last quantifiable plasma concentration (for single dose period only) of BMS-911543 and it's metabolite Met4	Day -1, Day 1, Day 8, Day 15, Day 21 and Day 28 or off-study
Area Under the Concentration-time Curve in One Dosing Interval (AUC(TAU)) of BMS-911543 and it's Metabolite Met4	Pharmacokinetic parameters of BMS-911543 and BMS-926796 (Met4) metabolite, will be derived from plasma concentration versus time. The pharmacokinetic parameters to be assessed include: AUC (TAU) = Area under the concentration-time curve in one dosing interval of BMS-911543 and it's metabolite Met4	Day -1, Day 1, Day 8, Day 15, Day 21 and Day 28 or off-study
The Terminal-phase Elimination Half-life in Plasma (T-HALF) of BMS-911543 and it's Metabolite Met4	Pharmacokinetic parameters of BMS-911543 and BMS-926796 (Met4) metabolite, will be derived from plasma concentration versus time. The pharmacokinetic parameters to be assessed include: T-HALF = The terminal-phase elimination half-life in plasma of BMS-911543 and it's metabolite Met4	Day -1, Day 1, Day 8, Day 15, Day 21 and Day 28 or off-study
Apparent Total Clearance (for Parent Compound Only) (CLT/F) of BMS-911543 and it's Metabolite Met4	Pharmacokinetic parameters of BMS-911543 and BMS-926796 (Met4) metabolite, will be derived from plasma concentration versus time. The pharmacokinetic parameters to be assessed include: CLT/F = Apparent total clearance (for parent compound only) of BMS-911543 and it's metabolite Met4	Day -1, Day 1, Day 8, Day 15, Day 21 and Day 28 or off-study
Apparent Volume of Distribution After First Dosing Based on the Terminal Phase (for Parent Compound Only) (Vz/F) of BMS-911543 and it's Metabolite Met4	Pharmacokinetic parameters of BMS-911543 and BMS-926796 (Met4) metabolite, will be derived from plasma concentration versus time. The pharmacokinetic parameters to be assessed include: Vz/F = Apparent volume of distribution after first dosing based on the terminal phase (for parent compound only) of BMS-911543 and it's metabolite Met4	Day -1, Day 1, Day 8, Day 15, Day 21 and Day 28 or off-study
Accumulation Index (AI): Ratio of AUC(TAU) on Day 15 to AUC(TAU) After the First Dose of BMS-911543 and it's Metabolite Met4	Pharmacokinetic parameters of BMS-911543 and BMS-926796 (Met4) metabolite, will be derived from plasma concentration versus time. The pharmacokinetic parameters to be assessed include: Accumulation index (AI) = ratio of AUC(TAU) on Day 15 to AUC(TAU) after the first dose of BMS-911543 and it's metabolite Met4	Day -1, Day 1, Day 8, Day 15, Day 21 and Day 28 or off-study
Ratio of BMS-926796 AUC(INF) to BMS-911543 AUC(INF) After 1st Dose and BMS-926796 AUC(TAU) to BMS-911543 AUC(TAU) on Day 15 (AUC Ratio)	Pharmacokinetic parameters of BMS-911543 and BMS-926796 (Met4) metabolite, will be derived from plasma concentration versus time. The pharmacokinetic parameters to be assessed include: AUC Ratio = Ratio of BMS-926796 AUC(INF) to BMS-911543 AUC(INF) after 1st dose and BMS-926796 AUC(TAU) to BMS-911543 AUC(TAU) on Day 15	Day -1, Day 1, Day 8, Day 15, Day 21 and Day 28 or off-study

Collaborators and Investigators

• Sponsor: Bristol-Myers Squibb

Publications and helpful links

Helpful Links

• BMS clinical trial educational resource
• BMS Clinical Trial Patient Recruiting

Study record dates

Study Major Dates

• Study Start (Actual): April 7, 2011
• Primary Completion (Actual): November 19, 2015
• Study Completion (Actual): November 19, 2015

Study Registration Dates

• First Submitted: November 5, 2010
• First Submitted That Met QC Criteria: November 5, 2010
• First Posted (Estimate): November 7, 2010

Study Record Updates

• Last Update Posted (Actual): July 31, 2019
• Last Update Submitted That Met QC Criteria: July 29, 2019
• Last Verified: July 1, 2019

More Information

Terms related to this study

• Keywords: Advanced Cancer, Various, NOS
• Other Study ID Numbers: CA215-001